TLDR
- Q1 adjusted earnings per share reached $0.75, surpassing the $0.72 consensus estimate
- Quarterly revenue totaled $13.8 billion, driven by robust Eliquis sales
- Year-over-year net income declined 9% to $2.7 billion; diluted EPS fell 10%
- 2026 full-year outlook maintained: adjusted EPS between $2.80–$3.00, revenue of $59.5B–$62.5B
- Shares advanced roughly 0.5% in premarket activity to about $26.33
Pfizer launched 2026 on solid footing, delivering first-quarter results that exceeded Wall Street’s expectations and pushing shares up approximately 0.5% to $26.33 in premarket activity.
The pharmaceutical company reported adjusted earnings of $0.75 per share for the quarter, outpacing the analyst consensus of $0.72. Quarterly revenue reached $13.8 billion.
The anticoagulant medication Eliquis, among Pfizer’s most significant revenue generators, sustained its strong performance. The medication continues serving as a critical pillar while legacy products demonstrate better-than-anticipated resilience.
Chief Financial Officer David Denton highlighted 22% operational revenue expansion from newly launched and recently acquired products. This growth metric represents a foundation Pfizer aims to strengthen going forward.
Net profitability showed some weakness. The pharmaceutical firm recorded $2.7 billion in net income, representing a 9% decrease compared to the prior-year period. Diluted earnings per share settled at $0.47, marking a 10% year-over-year drop.
Company Maintains Annual Projections
Pfizer stood by its 2026 financial outlook, keeping intact the guidance originally communicated in December. Management continues to project adjusted earnings per share ranging from $2.80 to $3.00 and total annual revenue between $59.5 billion and $62.5 billion.
Wall Street analysts had been forecasting $2.96 per share in adjusted earnings and $61.4 billion in revenue, both figures falling comfortably within the company’s projected ranges.
The company also reiterated that no share repurchase activity is anticipated for 2026. This guidance remains unchanged regardless of business performance throughout the year.
Chief Executive Albert Bourla expressed optimism about the company’s trajectory. “We’re off to a strong start in 2026,” he remarked, highlighting favorable Phase 3 clinical trial results and promising mid-stage research data.
Bourla emphasized oncology and obesity treatment development as two therapeutic areas where he expects Pfizer to “positioned to lead.”
Looming Patent Expirations Present Headwinds
The approaching patent cliff represents one of Pfizer’s most significant near-term obstacles. Intellectual property protections covering major revenue-generating medications, including Eliquis, are scheduled to lapse before 2030.
Pfizer has implemented strategies to mitigate this impact. The organization has negotiated arrangements with generic drug manufacturers to prolong market exclusivity on select products, including Vyndaqel.
Additionally, the company has been supplementing its product portfolio through strategic acquisitions and internal drug development efforts to strengthen its pipeline.
The research and development pipeline continues progressing across numerous therapeutic areas, with oncology and obesity programs receiving particular emphasis from company leadership.
First-quarter revenue increased 5% year-over-year to $14.5 billion on a reported basis, exceeding market projections entering the earnings release.
The dual beat on both earnings and revenue delivered investors a clearer quarterly performance than many had anticipated.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
